Skip to main content

Table 1 Summary of HCMV-tetramer in HLA-A2 individual groups

From: Large scale analysis of pediatric antiviral CD8+ T cell populations reveals sustained, functional and mature responses

Age(yr.) (n = 469) 0–4 (n = 179) 5–9 (n = 97) 10–14 (n = 94) 15–19 (n = 50) 20–29 (n = 28) 60–92 (n = 21)
Number of tet(+) 55(31%) 43(44%) 49(52%) 28(46%) 15(54%) 12(57%)
CD8(%) 18.9 ± 4.7 21.5 ± 7.4 20.2 ± 6.9 20.3 ± 6.7 24.8 ± 7.1 23.2 ± 9.6
Tet(%) 0.19 ± 0.23 0.18 ± 0.25 0.22 ± 0.31 0.23 ± 0.19 0.41 ± 0.54 1.49 ± 1.79
Tet/CD8(%) 1.05 ± 1.30 0.85 ± 1.04 1.02 ± 1.36 1.14 ± 0.96 1.55 ± 1.71 5.76 ± 4.19
  1. HCMV-tetramer positive: Tet/CD8(+) Lymphocytes ≥ 0.05%